 |
0 Diseases |  |
123 Trials |
|
123 Trials |  |
2738 News |  |
| «12...2526272829303132333435...4142» |
- | Zoladex (goserelin acetate implant) / AstraZeneca, TerSera Therap, Arimidex (anastrozole) / AstraZeneca, Remedica, Evomate (raloxifene hydrochloride) / Shreya Life Sciences
Journal: Estrogens regulate glycosylation of IgG in women and men. (Pubmed Central) - Jun 15, 2019
Among men, goserelin increased G0F glycans, an effect blocked by testosterone through conversion to estradiol. These results establish estrogens as an in vivo modulator of IgG galactosylation in both women and men, defining a pathway by which sex modulates immunity.
- | Arimidex (anastrozole) / AstraZeneca, Remedica
Retrospective data, Journal: Follicle-Stimulating Hormone and Estradiol Levels in Japanese Women Treated with Toremifene and Anastrozole for Two Years - A Retrospective Analysis of Data from a Prospective Randomized Trial (Pubmed Central) - Jun 15, 2019
The serum E2 level in the TOR group did not change markedly over 24 months. When switching to other endocrine agents as adjuvant therapy for patients with breast cancer treated with TOR, the serum FSH level decreased to half of the preinitiation level, and one-tenth of the FSH levels was<20mIU/mL, while the postmenopausal serum E2 level was maintained.
- | vistusertib (AZD2014) / AstraZeneca
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA) (clinicaltrials.gov) - Jun 12, 2019
P1/2, N=72, Recruiting, Sponsor: Centre Leon Berard
When switching to other endocrine agents as adjuvant therapy for patients with breast cancer treated with TOR, the serum FSH level decreased to half of the preinitiation level, and one-tenth of the FSH levels was<20mIU/mL, while the postmenopausal serum E2 level was maintained. Trial completion date: May 2019 --> Jun 2020 | Trial primary completion date: May 2019 --> Nov 2019
- | Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date: ASPIRE: Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (clinicaltrials.gov) - Jun 11, 2019
P2, N=42, Recruiting, Sponsor: Emory University
Trial completion date: May 2019 --> Jun 2020 | Trial primary completion date: May 2019 --> Nov 2019 Trial completion date: Mar 2020 --> Jun 2020 | Trial primary completion date: Mar 2020 --> Jun 2020
- |||| Kisqali (ribociclib) / Novartis
Enrollment open, Combination therapy, Metastases: AMALEE: Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (clinicaltrials.gov) - Jun 11, 2019
P2, N=350, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Mar 2020 --> Jun 2020 | Trial primary completion date: Mar 2020 --> Jun 2020 Not yet recruiting --> Recruiting
- | Firmagon (degarelix) / Astellas, Ferring, NN1213 / Novo Nordisk
Trial completion: Impact of Estradiol Addback (clinicaltrials.gov) - Jun 7, 2019
P1, N=43, Completed, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Arimidex (anastrozole) / AstraZeneca, Remedica
And Fulv + CDK4/6i without AI (Maybe Anastrozole is not needed) (Twitter) - Jun 6, 2019
- | anastrozole / Generic mfg.
Trial completion, Adverse events: ORACLES: Radiotherapy - Anastrazole Concomitant : Evaluation of the Side Effects (clinicaltrials.gov) - May 30, 2019
P=N/A, N=490, Completed, Sponsor: Centre Oscar Lambret
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | everolimus / Generic mfg.
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer (clinicaltrials.gov) - May 30, 2019
P2, N=48, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Active, not recruiting --> Completed Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Jan 2019 --> Jan 2020
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, HEOR: PH002-TP-II: Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients (clinicaltrials.gov) - May 30, 2019
P2, N=257, Active, not recruiting, Sponsor: Palleos Healthcare GmbH
Trial completion date: Jan 2019 --> Jan 2020 | Trial primary completion date: Jan 2019 --> Jan 2020 Recruiting --> Active, not recruiting
- | Arimidex (anastrozole) / AstraZeneca, Remedica, Tamoxis (tamoxifen) / Bioprofarma
Journal, Gene Signature: Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer. (Pubmed Central) - May 29, 2019
The derived 10-year signature predicts risk of metastasis in patients with ER+/HER2- breast cancer similar to commercial signatures. The hypothesis that early and late prognostic signatures are significantly more informative than a single signature was rejected.
- | Arimidex (anastrozole) / AstraZeneca, Remedica, Tamoxis (tamoxifen) / Bioprofarma, Evomate (raloxifene hydrochloride) / Shreya Life Sciences
Retrospective data, Review, Journal: Risk-reducing medications for primary breast cancer: a network meta-analysis. (Pubmed Central) - May 29, 2019
However, long-term data on toxicities from tamoxifen are available while the follow-up toxicity data on unaffected women taking AIs is relatively short. Additional data from direct comparisons are needed to fully address the issues of breast cancer prevention by risk-reducing medications, with special regards to acceptability (i.e. the benefit/harm ratio).
- ||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion, Trial completion date, Metastases: To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer (clinicaltrials.gov) - May 29, 2019
P1, N=79, Completed, Sponsor: AstraZeneca
Additional data from direct comparisons are needed to fully address the issues of breast cancer prevention by risk-reducing medications, with special regards to acceptability (i.e. the benefit/harm ratio). Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2019
- |||||||||| AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New P3 trial, Combination therapy, Metastases: DAWNA-2: A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer (clinicaltrials.gov) - May 28, 2019
P3, N=426, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- || Arimidex (anastrozole) / AstraZeneca, Remedica
If T/E2 ratio is below 10, I prescribe anastrozole 1mg per day. If T/E2 is above 10, I recommend clomiphene citrate 50 mg every other day during 3 months before microTESE in NOA. (Twitter) - May 28, 2019
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients (clinicaltrials.gov) - May 24, 2019
P=N/A, N=90, Recruiting, Sponsor: University of Maryland
Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2019 Trial completion date: Mar 2019 --> Mar 2022 | Trial primary completion date: Mar 2018 --> Mar 2021
- | Zoladex (goserelin acetate implant) / AstraZeneca, TerSera Therap, Arimidex (anastrozole) / AstraZeneca, Remedica, Faslodex (fulvestrant) / AstraZeneca
Clinical, P2 data, Journal: Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study). (Pubmed Central) - May 22, 2019
P2
Trial completion date: Mar 2019 --> Mar 2022 | Trial primary completion date: Mar 2018 --> Mar 2021 F + G provides a promising new option for the treatment of premenopausal women with HR+, HER2-, tamoxifen-pretreated MBC.
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Trial completion date: Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole (clinicaltrials.gov) - May 21, 2019
P=N/A, N=44, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
F + G provides a promising new option for the treatment of premenopausal women with HR+, HER2-, tamoxifen-pretreated MBC. Trial completion date: Dec 2018 --> Dec 2019
- | exemestane / generics
Clinical, Journal: Long-term effect of exemestane therapy on bone mineral density supported by bisphosphonates: Results of 5-year adjuvant treatment in postmenopausal women with early-stage breast cancer. (Pubmed Central) - May 15, 2019
Oral Bis improves BMD of the FN in patients with osteoporosis. Five-year EXE treatment with proper addition of Bis helps maintain the BMD of the LS and FN at the sixth year.
- | Avastin (bevacizumab) / Roche
Trial completion date: Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance (clinicaltrials.gov) - May 15, 2019
P1, N=281, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Five-year EXE treatment with proper addition of Bis helps maintain the BMD of the LS and FN at the sixth year. Trial completion date: Sep 2019 --> Sep 2020
- | New P4 trial: Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT) (clinicaltrials.gov) - May 13, 2019
P4, N=218, Not yet recruiting, Sponsor: Ottawa Hospital Research Institute
- | NN1213 / Novo Nordisk
Trial primary completion date: Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer Patients (clinicaltrials.gov) - May 13, 2019
P=N/A, N=500, Enrolling by invitation, Sponsor: Chinese Academy of Medical Sciences
Trial completion date: Sep 2019 --> Sep 2020 Trial primary completion date: Nov 2017 --> Jan 2020
- | Arimidex (anastrozole) / AstraZeneca, Remedica
Journal, Combination therapy: Re: Combination Therapy with Clomiphene Citrate and Anastrozole is a Safe and Effective Alternative for Hypoandrogenic Subfertile Men. (Pubmed Central) - May 11, 2019
Trial primary completion date: Nov 2017 --> Jan 2020 No abstract available
- || miransertib (MK-7075) / Merck (MSD)
Enrollment closed, Combination therapy: Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole (clinicaltrials.gov) - May 9, 2019
P1b, N=40, Active, not recruiting, Sponsor: ArQule
No abstract available Recruiting --> Active, not recruiting
- |||| Kisqali (ribociclib) / Novartis
New P2 trial, Combination therapy, Metastases: FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer (clinicaltrials.gov) - May 8, 2019
P2, N=194, Recruiting, Sponsor: Fondazione Sandro Pitigliani
- | hydroxychloroquine / VG Lifesciences
Journal: ACCELERATED ONSET OF RETINAL TOXICITY FROM HYDROXYCHLOROQUINE USE WITH CONCOMITANT BREAST CANCER THERAPY. (Pubmed Central) - May 7, 2019
Concomitant breast cancer therapy may have a synergistic effect with HCQ leading to accelerated retinal toxicity. As such potential acceleration is poorly understood, patients on HCQ who are treated with concomitant chemotherapy should be considered for more frequent retinal screenings to maximize safety and preservation of vision.
- | Arimidex (anastrozole) / AstraZeneca, Remedica
Clinical, Journal: Exploratory Study of Associations Between DNA Repair and Oxidative Stress Gene Polymorphisms and Cognitive Problems Reported by Postmenopausal Women With and Without Breast Cancer. (Pubmed Central) - May 7, 2019
Mood dysregulation before therapy may predict persistent cognitive problems during therapy. ERCC5 genotype may influence frequency of cognitive problems after controlling for these risk factors.
- || Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date, Combination therapy: PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer (clinicaltrials.gov) - May 6, 2019
P2, N=87, Recruiting, Sponsor: Washington University School of Medicine
ERCC5 genotype may influence frequency of cognitive problems after controlling for these risk factors. Trial completion date: Apr 2025 --> Apr 2027 | Trial primary completion date: Dec 2020 --> Apr 2022
- | Apristor (onapristone XR) / Context Therap
Enrollment open, Combination therapy, Pan tumor: A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone (clinicaltrials.gov) - May 5, 2019
P2, N=84, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Apr 2025 --> Apr 2027 | Trial primary completion date: Dec 2020 --> Apr 2022 Not yet recruiting --> Recruiting
- ||| Arimidex (anastrozole) / AstraZeneca, Remedica
Rethink prescribing #Anastrozole. Men need #Estradiol. Estradiol may be more important in #Libido than TTh. @DrMohitKhera @ranjithramamd (Twitter) - May 5, 2019
- | Arimidex (anastrozole) / AstraZeneca, Remedica
Clinical, P2 data, Journal: Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC). (Pubmed Central) - Apr 30, 2019
Not yet recruiting --> Recruiting Although the study was terminated owing to the altered liver function, it showed that there was a trend to greater shrinkage of tumor in the combination group for ER-positive, HER2-negative postmenopausal breast cancer.
- || anastrozole / Generic mfg.
New P2 trial: CAP: Anastrazole and Clomiphene to Evaluate Hypogonadal Symptoms and Erectile Function (clinicaltrials.gov) - Apr 30, 2019
P2, N=25, Completed, Sponsor: Albany Medical College
- | Faslodex (fulvestrant) / AstraZeneca
Clinical, Journal, HEOR: Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK. (Pubmed Central) - Apr 27, 2019
Although the study was terminated owing to the altered liver function, it showed that there was a trend to greater shrinkage of tumor in the combination group for ER-positive, HER2-negative postmenopausal breast cancer. Results suggest that fulvestrant could potentially be a cost-effective option compared with other endocrine monotherapies (anastrozole, letrozole, and tamoxifen) for treating endocrine therapy-naïve, postmenopausal women with HR+, locally advanced or metastatic breast cancer.
- | Arimidex (anastrozole) / AstraZeneca, Remedica
Clinical, Journal: In case of anastrozole-related hallucinations, can switching to letrozole be a treatment option? A case report and literature review. (Pubmed Central) - Apr 26, 2019
The patient had no neuropsychiatric complaints during letrozole treatment. We aimed to emphasize that neurological side effect like hallucination may rarely occur during the treatment of anastrozole and in case of aromatase inhibitor-related hallucinations, switching to another aromatase inhibitor (letrozole) can be a treatment option.
- | Retrospective data, Review, Journal: Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis. (Pubmed Central) - Apr 26, 2019
Pal + AI, LEE + AI, Ful250 + AI, or Ful500 as first-line treatment for HR+/HER2- mBC had longer PFS than AI alone. Given the lack of head-to-head clinical trials comparing the efficacy of recently approved first-line ETs for HR+/HER2- mBC, these results have important clinical implications for the treatment of HR+/HER2- mBC in the first-line setting.
- | New trial: Breast Cancer Treatment Based on Organ-like Culture (clinicaltrials.gov) - Apr 23, 2019
P, N=300, Enrolling by invitation, Sponsor: Xijing Hospital
- ||| Arimidex (anastrozole) / AstraZeneca, Remedica
Combo therapy with Clomiphene & Anastrozole is safe and effective for T deficiency. @jimhotalingmd Male Infertility | Journal of Urology https://t.co/8T4Yfgad2C (Twitter) - Apr 23, 2019
- | anastrozole / Generic mfg., fulvestrant / Generic mfg.
Clinical, Journal: Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. (Pubmed Central) - Apr 20, 2019
P3
The results suggest that the benefit was particularly notable in patients without previous exposure to adjuvant endocrine therapy. (Funded by the National Cancer Institute and AstraZeneca; ClinicalTrials.gov number, NCT00075764.).
- ||| fexagratinib (ABSK091) / Abbisko
Trial completion, Trial completion date, Combination therapy: AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL) (clinicaltrials.gov) - Apr 20, 2019
P2a, N=56, Completed, Sponsor: Imperial College London
(Funded by the National Cancer Institute and AstraZeneca; ClinicalTrials.gov number, NCT00075764.). Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> Dec 2018
- | Arimidex (anastrozole) / AstraZeneca, Remedica
Preclinical, Journal: Acquired-resistance to aromatase inhibitors: where we stand! (Pubmed Central) - Apr 19, 2019
Moreover, clinical evidence demonstrated that there is a lack of cross-resistance among AIs, although the reason is not fully understood. Thus, there is a demand to understand the mechanisms involved in endocrine resistance to each AI, since the search for new strategies to surpass breast cancer acquired resistance is of major concern.
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, HEOR: PH002-TP-II: Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients (clinicaltrials.gov) - Apr 18, 2019
P2, N=257, Recruiting, Sponsor: Palleos Healthcare GmbH
Thus, there is a demand to understand the mechanisms involved in endocrine resistance to each AI, since the search for new strategies to surpass breast cancer acquired resistance is of major concern. Trial completion date: Nov 2024 --> Feb 2024
- |||| Kisqali (ribociclib) / Novartis
Enrollment open, Metastases: RIGHT Choice: Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Apr 16, 2019
P2, N=222, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Nov 2024 --> Feb 2024 Not yet recruiting --> Recruiting
- ||| Ibrance (palbociclib) / Pfizer
Enrollment closed, Metastases: INGE-B: Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant (clinicaltrials.gov) - Apr 10, 2019
P2, N=388, Active, not recruiting, Sponsor: iOMEDICO AG
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Kisqali (ribociclib) / Novartis
Trial initiation date, Combination therapy, Metastases: AMALEE: Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (clinicaltrials.gov) - Apr 10, 2019
P2, N=350, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Initiation date: Oct 2019 --> Jun 2019
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New P2 trial: Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC (clinicaltrials.gov) - Apr 10, 2019
P2, N=250, Not yet recruiting, Sponsor: Peking Union Medical College Hospital
- | Arimidex (anastrozole) / AstraZeneca, Remedica
Journal: Biophysical characterization of Aptenodytes forsteri cytochrome P450 aromatase. (Pubmed Central) - Apr 9, 2019
The time-dependent changes in the Soret bands observed in stopped-flow mixing experiments of the steroidal ligands and the inhibitor anastrozole with afCYP19 were best described by a two-step binding mechanism. In summary, these studies describe the first biophysical characterization of an avian aromatase that displays strikingly similar enzyme kinetics and ligand binding properties to the human enzyme and could serve as a convenient model system for studies of the enigmatic transformation of androgens to estrogens.
- | Kisqali (ribociclib) / Novartis
Clinical, P3 data, Journal: Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. (Pubmed Central) - Apr 9, 2019
P3
Ribociclib plus endocrine therapy improved progression-free survival compared with placebo plus endocrine therapy, and had a manageable safety profile in patients with premenopausal, HR-positive, HER2-negative, advanced breast cancer. The combination could represent a new first-line treatment option for these patients.
- | Arimidex (anastrozole) / AstraZeneca, Remedica
Preclinical, Journal: Preparation and in vitro/in vivo evaluation of anastrozole reservoir-type intravaginal ring. (Pubmed Central) - Apr 9, 2019
The mass transition ion-pair was followed as m/z from 294.10 to 225.08 for anastrozole and m/z from 386.23 to 122.11 for buspirone. The results proved that the correlation between in vitro and in vivo was relatively well.
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: SEAT: Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients (clinicaltrials.gov) - Apr 9, 2019
P2, N=110, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
The results proved that the correlation between in vitro and in vivo was relatively well. Trial completion date: Nov 2019 --> Dec 2020 | Trial primary completion date: May 2019 --> Dec 2019
- | Apristor (onapristone XR) / Context Therap
New P2 trial, Combination therapy, Pan tumor: A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone (clinicaltrials.gov) - Apr 8, 2019
P2, N=84, Not yet recruiting, Sponsor: Memorial Sloan Kettering Cancer Center